NCT03370653View on ClinicalTrials.gov

A Study in MPS VI to Assess Safety and Efficacy of Odiparcil

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 30, 2017

Primary Completion Date

September 24, 2019

Study Completion Date

October 22, 2019

Conditions
Mucopolysaccharidosis VI
Interventions
DRUG

Odiparcil

Investigational product: odiparcil 250 mg tablets

OTHER

Placebo

Comparator: placebo tablets similar to odiparcil 250 mg tablets

Trial Locations (4)

55131

Villa Metabolica, Mainz

69500

Hôpital Femme-Mère-Enfant, Bron

4200-319

Centro Hospitalar S. João, Porto

NW3 2QG

Royal Free Hospital, London

Sponsors

Lead Sponsor

Inventiva Pharma
All Listed Sponsors
lead

Inventiva Pharma

INDUSTRY

NCT03370653 - A Study in MPS VI to Assess Safety and Efficacy of Odiparcil | Biotech Hunter | Biotech Hunter